<DOC>
	<DOCNO>NCT00305643</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high energy x-ray kill tumor cell . Drugs use chemotherapy , capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving radiation therapy together capecitabine may kill tumor cell . Celecoxib may prevent lessen hand-foot syndrome cause capecitabine . PURPOSE : This randomized phase III trial study well celecoxib work prevent hand/foot syndrome cause capecitabine patient metastatic breast colorectal cancer .</brief_summary>
	<brief_title>Celecoxib Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy celecoxib reduce incidence severity hand/foot syndrome cause capecitabine patient metastatic breast cancer colorectal cancer . OUTLINE : This placebo-controlled , randomize , double-blind , multicenter study . Patients stratify accord metastatic disease ( breast v colorectal ) , ECOG performance status ( 0 1 v 2 ) , prior chemotherapy ( yes v ) . Patients receive 1 2 treatment regimen . - Regimen A ( concurrent radiotherapy ) : Patients undergo radiotherapy 5 day week 5-6 week receive oral capecitabine twice daily 5 day week . Following completion radiotherapy , patient may continue oral capecitabine regimen B . - Regimen B ( radiotherapy ) : Patients receive oral capecitabine daily day 1-14 . Courses repeat every 21 day . Patients also randomize 1 2 treatment arm . - Arm I : Patients receive oral celecoxib twice daily day 1-21 . - Arm II : Patients receive oral placebo twice daily day 1-21 . In arm , treatment repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month . PROJECTED ACCRUAL : A total 342 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>1 . Patients metastatic colorectal cancer breast cancer scheduled*** receive capecitabine initial dose range 7501500 mg/m2** twice daily ( total daily dose range 15003000 mg/m2 ) alone combination one agent . ***Patients may enter study receive capecitabine 21 day prior study entry . **Doses may round upward downward per physician discretion utilize 500mg tablet . 2 . Patients either metastatic colorectal metastatic breast cancer may receive number type prior treatment regimens metastatic disease may receive prior treatment metastatic disease . 3 . Men woman ethnic racial group . 4 . &gt; /= 18 year old 5 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; /= 2 6 . Adequate organ function : . Total bilirubin &lt; /= 1.5 * institutional uppernormal limit ( IUNL ) b. aspartate aminotransferase ( AST SGOT ) alanine aminotransferase ( ALT SGPT ) &lt; /= 2.5 * IUNL c. Patients liver mets AST/ ( SGOT ) and/or ALT ( SGPT ) &lt; 5 * IUNL d. Alkaline phosphatase &lt; /= 5 * IUNL e. Creatinine Clearance &gt; 50 ml/min 7 . Adequate bone marrow function : ( ) Leukocytes &gt; /= 3,000/microL ; ( b ) Absolute neutrophil count &gt; /= 1,500/microL ; ( c ) Platelets &gt; /= 100,000/microL 8 . Women childbearing age men must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation . 9 . Negative pregnancy test woman childbearing age . 10 . Must ability understand willingness provide write informed consent participate study . 11 . Controlled brain metastasis ( i.e . stereotactic surgery , surgery steroid , anticonvulsant ) . 1 . History allergy sulfonamide , aspirin , NSAID ( Nonsteroidal antiinflammatory drug ) 5FU COX2 inhibitor . 2 . Any regular use COX2 inhibitor , NSAIDS aspirin &gt; 325 mg twice week . 3 . Pregnancy lactation . 4 . History significant neurological psychiatric disorder would impede give consent , treatment followup . 5 . Any serious illness medical condition : uncontrolled congestive heart failure , uncontrolled hypertension arrhythmia , active angina pectoris , history myocardial infarction , stroke transient ischemic attack ( TIA ) . 6 . Serious uncontrolled active infection . 7 . Patients comply take document oral study medication . 8 . History active peptic ulcer disease upper gastrointestinal ( GI ) bleed within 12 month enrollment . 9 . Use warfarin . 10 . Patients uncontrolled brain metastasis . 11 . Patients may prior Handfoot syndrome ( HFS ) must completely resolve &gt; /= 4 week . 12 . No concurrent radiation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Hand-Foot Syndrome</keyword>
	<keyword>cancer-related problem/condition</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>pain</keyword>
	<keyword>palmar-plantar erythrodysesthesia</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>Celecoxib</keyword>
	<keyword>Celebrex</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Xeloda</keyword>
</DOC>